The therapeutic landscape of small cell lung cancer (SCLC) is undergoing a paradigm shift with the emergence of delta-like ligand-3 (DLL3)–directed therapies, particularly tarlatamab, a first-in-class ...

Ligand Pharmaceuticals’ topical skin infection gel Zelsuvmi is changing hands again—sort of. After Ligand last year created Pelthos Therapeutics to support the launch of Zelsuvmi, Pelthos is ...

In the pre-market trading, Ligand is 0.65% higher at $105.30 on the Nasdaq. Wednesday, Channel had closed 3.46% lesser at $1.2550 on the New York Stock Exchange.

Ligand and investors are contributing $50 million to support the Pelthos-Channel merger, set to close summer 2025. FDA-approved Zelsuvmi is the first at-home prescription for molluscum, a skin ...

Predicting protein-ligand binding affinities is a critical problem in drug discovery and design. A majority of existing methods fail to accurately characterize and exploit the geometrically invariant ...

“Our model excels in optimizing ligand binding affinity based solely on initial protein sequences and ligand SMILES strings, bypassing the need for detailed structural data,” Hy said. “These findings ...

Simplified redesign of proteins to improve ligand binding Date: January 21, 2025 Source: University of Alabama at Birmingham Summary: The ability to alter proteins to refine control over binding ...

The analysis of protein-ligand binding sites plays a crucial role in the initial stages of drug discovery. Accurately predicting the ligand types that are likely to bind to protein-ligand binding ...

Visible-Light-Antenna Ligand-Enabled Samarium-Catalyzed Reductive Transformations. Journal of the American Chemical Society , 2024; 146 (30): 20904 DOI: 10.1021/jacs.4c05414 Cite This Page : ...

Rathkopf D, Patel MR, Choudhury AD, et al. Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts ...

The data show that the ligand reacts with α-synuclein aggregates in all three synucleinopathies. “Our work has offered a benchmark for the development of α-synuclein PET tracers by showing that a ...

Actual events or results may differ from Ligand's expectations due to risks and uncertainties inherent in Ligand’s business, including, without limitation: the risk that Ligand and Pelthos may not ...